Moleculin's Annamycin Shows 40% CRc Rate in Early AML Trial Data — Moleculin Biotech, Inc.

Event summary

Moleculin's MIRACLE trial for Annamycin in AML patients shows a preliminary 40% CRc rate in the first 30 subjects treated.
The trial is on track to treat the first 45 subjects by Q1 2026, with unblinding expected thereafter.
Approximately 35% of subjects treated so far are venetoclax regimen failures, a challenging patient population.
Annamycin has demonstrated no cardiotoxicity in prior trials, positioning it as a potential advancement in AML treatment.

The big picture

Moleculin's Annamycin is positioned as a non-cardiotoxic alternative to existing anthracyclines, addressing a significant unmet need in the relapsed/refractory AML market. The preliminary data from the MIRACLE trial suggests a potential shift in the treatment landscape for this challenging patient population. The absence of cardiotoxicity and the high efficacy rates observed could make Annamycin a compelling option for patients who have failed other therapies.

What we're watching

Trial Execution: Whether Moleculin can sustain the current recruitment pace and meet the Q1 2026 milestone for treating 45 subjects.
Regulatory Pathway: How the upcoming unblinding data will influence the regulatory strategy for Annamycin's approval.
Market Positioning: The pace at which Moleculin can leverage these results to attract potential partners or investors.